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Abstract
Background: Increasing attention is being paid to variations in the use of prescription drugs because their role in health
care has grown to the point where their use can be considered a proxy for health system performance. Studies have shown
that prescription drug use varies across regions in the US, UK, and Canada by more than would be predicted based on age
and health status alone. In this paper, we explore the determinants of variations in the use of prescription drugs, drawing on
health services theories of access to care.
Methods: We conducted a cross-sectional analysis using population-based administrative health care data for British
Columbia (BC), Canada. We used logistic and hierarchical regressions to analyze the effects of individual- and area-level
determinants of use of prescriptions overall and rates of purchase of prescriptions from five therapeutic categories
representing a range of indications: antihypertensives, statins, acid reducing drugs, opioid drugs, and antidepressants. To
indicate the relative scale of regional variations and the importance of individual- and area-level variables in explaining
them, we computed standardized rates of utilization for 49 local health areas in BC.
Results: We found that characteristics of individuals and the areas in which they live affect likelihood of prescription drug
purchase. Individual-level factors influenced prescription drug purchases in ways generally consistent with behavioral
models of health services use. Contextual variables exerted influences that differed by type of drug studied. Population
health, education levels, and ethnic composition of local areas were associated with significant differences in the likelihood
of purchasing medications. Relatively modest regional variations remained after both individual-level and area-level
determinants were taken into account.
Conclusions: The results of this study suggest that individual- and area-level factors should be considered when studying
variations in the use of prescription drugs. Some sources of such variations, including individual- and area-level
socioeconomic status, warrant further investigation and possible intervention to address inequities.
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Introduction
Many studies have shown that medical and surgical practices
vary across regions and/or populations by more than would be
expected based on medical needs alone [1,2,3,4,5,6,7,8]. These
variations are increasingly viewed as indicators of health system
performance and of the quality of care received by populations
because they can be costly in terms of both financial expense and
health outcomes [6,7,8]. Although much more is known about
regional variations in the use of other health care services,
increasing attention is being paid to variations in the use of
prescription drugs because their role in health care has grown to
the point where their use can be considered a proxy for health
system performance. Studies have shown that prescription drug
use varies across regions in the US, UK, and Canada by more
than would be predicted based on age and health status alone
[9,10,11,12,13]. Some of these studies indicate that area-level
factors such as ethnic composition, physician supply, and
socioeconomic status may partially explain regional variations in
medicine use [10,11,13].
We have previously demonstrated that prescription drug use
and cost varies across Canadian provinces[14,15] and across
regions within provinces[16,17] by more than might be expected
based on variations in population age and health status. Using
administrative health care data that cover virtually all of the 4
million residents of British Columbia (BC), Canada, and informed
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15883by health services research theories concerning access to care, we
aimed to test hypotheses about the extent to which variations in
the use of medicines may be explained by the characteristics of
individuals and/or by the characteristics of the communities in
which they live. We first tested models of prescription drug use
that included only individual-level factors such as age, sex, health
status, and income. We then added area-level contextual factors
such as primary care supply, population health, and ethnic
concentration. After testing these in logistic regression analyses, we
illustrated the effects that accounting for individual- and area-level
characteristics had on measures of regional variations in prescrip-
tion drug use using summary measures of variation.
We conducted our analysis using population-based administra-
tive health care datasets covering virtually all of the 4 million
residents of BC. Because the extent of variation in the use of
prescription drugs (across regions and population subgroups) is
greater for specific therapeutic categories than for all categories
combined [14,15,16,17], we studied variations in the prevalence of
prescription drug purchases from five therapeutic categories
representing a range of indications.
Context
BC is a geographically, economically, and culturally diverse
province of Canada, with a population of approximately 4.1
million (data for 2006). The province covers an area nearly the size
of France and Germany combined; however, approximately 85%
of the population is concentrated in just a few urban areas,
especially in southern regions close to the Canada-US border.
Over half of the residents of BC (,2.1 million) live in the
metropolitan area of Vancouver alone. As of the 2006 Census, the
median income per family in BC was CAD$62,000, with the
major economic activities being financial services (25% of
provincial GDP), manufacturing (8%), transportation (6%), and
energy (5%) [18]. In 2006, an estimated 27% of the population of
BC (,1.1 million people) were immigrants to Canada, more than
half of whom emigrated from Asia [19].
Residents of BC are covered under a universal public health
insurance system that provides full first-dollar coverage for medical
and hospital care. BC residents may also register for the Fair
PharmaCare program, which provides public subsidy of prescrip-
tion drug costs that exceed deductibles set at certain percentages of
household income. Deductibles for persons born prior to 1939 are
relatively low; for all other residents, deductibles are set at
gradually increasing percentages of income and reach a maximum
of 3% of household income for all households with incomes
exceeding CAD$30,000. Because of the structure of the program,
a majority of households in BC face considerable deductibles
before any public drug benefits are provided. Many residents have
supplementary (usually employment-related) private health insur-
ance that covers prescription drugs. Private insurance plans are
estimated to cover approximately 40% of total prescription drug
expenditures, public programs another 40%, and out-of-pocket
payments are estimated to account for 20% [20].
Methods
Ethics statement
With permission from data stewards at the BC Ministry of
Health Services and the College of Pharmacists of BC, and the
approval of the University of British Columbia research ethics
board, we conducted this study using de-identified linked datasets
from Population Data BC and BC PharmaNet. Informed consent
from patients is not required for use of these de-identified
administrative databases.
Framework
We based our analysis on a modified version of the Andersen,
Newman, Aday framework with three dimensions of patient
characteristics that act as predictors of health care use: predisposing
characteristics, such as age and sex; enabling resources, such as
income and insurance; and needs, such as diagnosed illness [21,22,
23]. Based on a model described by Phillips and colleagues, we
included contextual variables that describe the setting in which use
of care occurs [24]. In particular, we explored community-level
factors such as the availability of primary care providers, overall
population health, average incomes, rates of post-secondary
education, and ethno-cultural mix.
Data and cohort
Our datasets contained records of every filled prescription,
hospital discharge, and fee-for-service medical visit during
calendar year 2006 for every resident of BC except status Indians,
veterans, and Royal Canadian Mounted Police, who are federally
covered for healthcare (,5% of the total provincial population).
The BC PharmaNet database tracks every prescription dispensed
from community pharmacies and long-term care facilities,
regardless of patient age or insurance status; however, it excludes
prescription drugs used within acute care hospitals.
To ensure complete data capture for study subjects, we
excluded any resident who lived in BC for fewer than 275 days
in 2006 (,6% of the population). To provide for reasonable
comparability of health system and social contexts, we excluded
rural and remote areas of BC (,6.5% of the population). The
resulting cohort contained 3.92 million residents (,84.1% of the
total provincial population, 89.6% of the population within the
non-rural regions studied).
Outcomes Variables
In previous work, we found that the most significant factor
contributing to regional variations in the cost and volume of
prescription medicines used is variation in the likelihood that
individuals will fill one or more prescriptions [16,17]. Our primary
outcomes in this study were therefore period prevalence measures
of prescription drug purchases during the calendar year of 2006.
We created binary outcomes variables indicating whether a person
filled one or more prescriptions from each of five therapeutic
categories: antihypertensives, statins, acid-reducing drugs, opioid
drugs, and antidepressants. These categories represent a range of
primary indications and include some that may be deemed less
discretionary than others (e.g., antihypertensives versus antide-
pressants); non-medical factors at the individual and area level
may have a greater impact on use of discretionary medicines.
Appendix S1 contains a list of the specific types of drug included in
each drug class analyzed.
Individual-Level Explanatory Variables
For every person in our sample, we constructed measures of
general and condition-specific health care needs using the Johns
Hopkins University ACG Case-Mix System [25]. The ICD-9/
ICD-10 diagnostic codes for this came from hospital discharge
records (up to 25 codes per discharge) and billings for fee-for-
service medical visits (one code per visit). We used a count of the
Aggregated Diagnostic Groups (ADGs) as a general health status
measure: a higher count of ADGs indicates greater clinical
complexity. We used Expanded Diagnostic Clusters (EDCs) to
indicate the presence of common indications (e.g., hypertension)
for each drug class studied (e.g., antihypertensives); Appendix S1
contains a list of the EDCs used for each drug class.
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while our individual-level enabling variable was relative income
ranking (in deciles). For approximately 80% of our sample, income
rankings were based on household-specific tax-return data
maintained by the province for the purpose of administering the
Fair PharmaCare program. For the remaining population, income
ranks were assigned based on neighborhood income estimates
provided by Statistics Canada [26].
Area-level Explanatory Variables
Our geographic units of analysis are local health areas (LHAs),
used for planning health services delivery in BC. The 49 predo-
minantly urban LHAs studied ranged in population size from
8,683 to 298,253 (median =45,744). To gauge population health
within each LHA, we obtained from BC Stats the average
potential years of life lost (PYLL) due to natural causes between
2003 and 2007. We used the share of 2006 Census respondents
that reported being Chinese, South Asian, or another visible
minority to provide information about the ethnic composition of
LHAs. (Area-level immigration was highly correlated with
prevalence of Chinese ethnicity and therefore not included in
our models.) To measure LHA socioeconomic characteristics, we
used 2006 Census data on average household incomes and
percentage of population over age 20 with some post-secondary
education. Finally, we obtained published estimates of the number
of full-time equivalent primary care physicians per 100,000
residents within each LHA during 2006 to measure primary
health care supply [27].
Statistical models
For each outcome, we ran two regression models: the first
controlled for individual-level independent variables only and the
second controlled for individual- and area-level independent
variables. We used generalized estimating equation (GEE) models
to account for clustering at the LHA. Owing to the large size of
our database, we were unable to run those models on the full
dataset (3.293 million observations). We therefore ran the multi-
level GEE models on a 2% random sample of the full dataset
(62,459 observations) and logistic regressions on the sample and
full datasets. Estimates of standard errors in the logistic models
were adjusted for clustering of individuals within LHAs. We
compared the goodness of fit for models with and without the
area-level variables using log-likelihood ratio tests.
To determine the effects that accounting for individual- and
area-level characteristics have on measures of regional variation in
prescription drug use, we used the regression models to compute
standardized rates of utilization for each LHA. The standardized
utilization rate can be interpreted as what the provincial rate
would be if people in all areas of the province used medicines (or
other health services) at the same age-, sex-, health-, and income-
adjusted rates as residents in the specified LHA and, when area-
level variables are included, if all areas of the province had the
same contextual characteristics as the LHA in question. Using
these standardized rates, we computed summary statistics and
coefficients of variation to gauge the impact of the area-level
contextual variables on the measured variation across LHAs. All
analyses were run on STATA version 10.0 (StataCorp LP).
Results
Table 1 describes the individual- and area-level characteristics
of our study population. Our study sample included 3,292,605
individuals living in 49 non-rural LHAs. The sample age (40.2)
and sex (51% female) distribution was equal to census figures for
the province. Residents in our sample had diagnoses in their
administrative health records that indicated an average of 3.2
ADGs in 2006. The LHAs included in this study varied
moderately (coefficient of variation, CV.0.20) in terms of
population health (PYLL), average income, and primary health
care supply; LHAs varied considerably (CV.1.00) in terms of
percentages of Chinese and South Asian populations. Of the drug
types studied, antihypertensives (15%), opioids (12%), and
antidepressants (10%) were most commonly used.
Determinants of utilization
Likely because the correlation of errors within clusters was low,
results of the GEE models on a 2% sample of the data and logistic
models were virtually identical – all adjusted odds ratios were
equal to the third or fourth decimal and no tests of statistical
significance changed [28]. Table 2 lists results from the full sample
logistic regressions for prescription drug purchases by therapeutic
category. All five of the models containing only individual-level
variables suggest that individual-level health needs, predisposing
factors and enabling factors are significant for explaining
variations in prescription drug use (p,0.001). Moreover, individ-
ual-level health needs and predisposing factors had expected
impacts on the likelihood of category-specific prescription
purchases. There was a u-shaped relationship between income
and the likelihood of purchasing drugs from each class studied
except for opioids (for which there was a negative income
gradient).
Adjusted odds ratios on individual-level variables did not
change significantly when area-level variables were added to the
model, and the models containing both individual- and area-level
variables were better fit (LR test, p,0.001), though the change in
the predictive power of the model was very modest (small changes
Table 1. Characteristics of the study population.
Variable Result CV
Sample size 3,292,605
Individual-level characteristics
Female share 0.51
Age mean 40.2 0.55
Overall needs, mean # of ADGs 3.2 0.88
Contextual (area-level) characteristics
Potential years life lost, mean 32.8 0.25
Chinese share 0.11 1.27
South Asian share 0.07 1.29
Other minority share 0.09 0.67
Post-secondary share 0.62 0.13
Average income, $1000s 69.1 0.20
Primary care supply, mean FTE/100,000 residents 8.6 0.27
Use of prescription drugs (% province-wide)
Antihypertensives 0.15 2.40
Statins 0.07 3.71
Acid reducing drugs 0.08 3.38
Opioids 0.12 2.67
Antidepressants 0.1 3.00
CV = coefficient of variation.
doi:10.1371/journal.pone.0015883.t001
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likelihood of purchasing drugs of different types. The level of
population health needs (PYLL) was positively associated with the
likelihood of purchasing antidepressants and opioid drugs and
negatively associated with the likelihood of purchasing statins.
Higher concentrations of ethnic minorities in LHAs were generally
associated with a lower likelihood of prescription purchases, but
the results varied by drug category. For example, the share of the
local population that identified as Chinese was negatively asso-
ciated with the likelihood of purchasing antidepressants and opioid
drugs but not significantly associated with the likelihood of
purchasing antihypertensives, statins, or acid-reducing drugs.
Area-level supply of primary care physicians was not significantly
associated with the likelihood of purchasing any of the five types of
medicine studied.
Impact on measures of regional variations
Table 3 lists summary statistics describing the distribution across
LHAs of prevalence rates for prescription drug purchases from the
five therapeutic categories. The table summarizes variations in
crude rates of medicine use, as well as standardized rates based on
predictions from the logistic regression with adjustments for
individual-level determinants and from the logistic regression with
adjustments for individual- and area-level determinants. The
magnitude of variation in crude rates of prescription purchases
across regions was comparable for all five drug classes studied. The
extent to which measured regional variation was attenuated by the
addition of individual- and area-level predictors of drug use
differed by specific type of prescription drug.
The addition of individual-level variables to create adjusted
measures of prevalence reduced measures of regional variation in
the purchase of each type of prescription drug; however, measured
variation fell most notably for antihypertensives and statins
when individual-level factors were accounted for. The CVs for
these categories changed from 0.18 to 0.07 and 0.20 to 0.11,
respectively. The addition of individual-level variables had the
least effect on measures of regional variation in the purchase of
antidepressants and opioid drugs. In contrast, while the addition of
area-level variables to the adjustment model reduced measured
variations for all drug types, the effects of area-level variables were
greatest for measured variation in the use of antidepressants and
opioid drugs - the CVs for these categories changed from 0.17 to
0.07 and 0.16 to 0.07, respectively, with the addition of area-level
variables.
Table 2. Adjusted odds ratios for the likelihood of purchasing one or more prescription from specific therapeutic categories in
2006, non-rural local health areas of British Columbia.
Antihypertensives Statins Acid reducing drugs Opioid drugs Antidepressants
A B ABA B ABAB
Needs
Overall needs (# of ADGs) 1.069** 1.070** 1.095** 1.094** 1.262** 1.263** 1.242** 1.245** 1.143** 1.146**
Treatment-specific need
1 27.658** 27.817** 7.438** 7.373** 18.165** 17.639** 3.223** 3.129** 7.840** 7.751**
Predisposing (sex, age
2)
Female (Male = ref) 1.193** 1.196** 0.663** 0.665** 1.094** 1.098** 0.818** 0.819** 1.432** 1.438**
Age 10–14 (50–54= ref) 0.023** 0.023** 0.001** 0.001** 0.110** 0.109** 0.134** 0.132** 0.097** 0.095**
Age 30–34 (50–54= ref) 0.223** 0.226** 0.073** 0.073** 0.396** 0.400** 0.905** 0.920** 0.587** 0.598**
Age 70–74 (50–54= ref) 2.988** 2.970** 4.411** 4.475** 1.788** 1.785** 0.762** 0.756** 0.795** 0.785**
Age 90–94 (50–54= ref) 4.069** 4.072** 1.123* 1.165** 1.645** 1.661** 0.566** 0.561** 0.887* 0.869**
Enabling (income
2)
Lowest decile (middle = ref) 1.103** 1.135** 1.188** 1.188** 1.337** 1.356** 1.276** 1.317** 1.569** 1.627**
3rd income decile (middle = ref) 0.952* 0.969 1.042* 1.021 1.023 1.031* 1.003 1.043 0.958 1.005
7th income decile (middle = ref) 1.039* 1.037** 1.067** 1.077** 1.018 1.023 0.992 0.980* 1.001 0.989
Highest income decile (middle = ref) 1.157** 1.187** 1.215** 1.264** 1.076** 1.120** 0.947* 0.966* 1.001 1.023
Contextual (area-level)
Potential years life lost 1.002 0.996* 1.001 1.004** 1.006**
Chinese share 0.999 1.001 0.999 0.988** 0.987**
South Asian share 0.997 1.008** 1.000 0.997 0.996*
Other minority share 0.992* 0.999 0.993** 0.995* 0.990**
Post-secondary share 0.990** 0.985** 0.997 0.994* 0.998
Average income ($1000s) 1.001 1.001 0.997** 1.000 0.999
Primary care supply 1.012 1.008 0.992 0.999 1.006
C-statistic (%) 95.65 95.67 91.05 91.12 86.24 86.29 80.47 80.79 87.37 87.66
A = individual level, B = individual and area level
1 = table shows odds ratio for only one Expanded Diagnostic Clusters (EDC) from in each category-specific logistic regression model. Appendix S1 contains a complete
list of diagnoses used for each category-specific analysis.
2 = table shows only examples of the 20 age groups and 10 income groups.
*= significant at or below p=0.05.
**= significant at or below p=0.01.
doi:10.1371/journal.pone.0015883.t002
Determinants of Variation in Prescription Drug Use
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15883Discussion
Our results provide evidence indicating that the characteristics
of individuals and of the areas in which they live affect likelihood
of prescription drug use and that these characteristics may help to
explain regional variations in prescription drug use. Beyond the
expected contributions of individual-level factors, which influenced
prescription drug use in ways generally consistent with behavioral
models of health services use, area-level variables were important
determinants of regional variations in use. For example, area-level
measures of population health and socioeconomic status affected
the likelihood of purchasing several types of prescription drugs;
similarly, area-level concentrations of one or more ethnic
minorities were negatively associated with purchases of all types
of medicine studied except statins. Because these area-level factors
vary considerably across regions, their addition to statistical
models significantly reduced measures of regional variations in
(adjusted) rates of prescription drug use.
Our measures of variation that standardize for individual-level
factors only are comparable to health status stratified results that
Dubois and colleagues documented for 1998/99 in California
[29]. Though no study has factored area-level characteristics into
measures of regional variations, previous studies have found
similar influences concerning area-level factors and use of specific
prescription drugs. In a study of stimulant use among insured
children in the US, Cox and colleagues found average income and
the proportion of whites within neighborhoods were positively
associated with the likelihood of stimulant use but that there was
no association between physician supply and stimulant use [13].
Analyzing rates of treatment for anxiety and depression in 39
deprived areas of England at an ecological level, Goyder and
colleagues found that prescribing rates were positively associated
with the supply of general practitioners and negatively associated
with the share of the population for whom English was not their
first language [11]. Finally, also using a form of ecological analysis,
Ward and colleagues found a negative association between statin
prescribing and the share of ethnic minorities in the populations
served across 132 GP practices in northwest England [10].
Limitations
Several limitations of our study should be noted. For certain
constructs, we were unable to generate corresponding measures at
the individual and area level. Most notably, we were unable to
identify ethnicity and immigration at the individual level for this
study population because such data are not routinely collected in
Canada. Coefficients on our area-level ethnicity variables may
therefore have explanatory power in our models because they
serve, in part, as proxies of individual-level ethnicity. Additionally,
because our health status measures were constructed based on
data derived from contacts with the health care system, our
research methods may understate the level of health needs for
groups who experience economic, cultural, or other demonstrable
barriers to accessing health care. In analyses done to test for this,
we did not find significant evidence of access barriers to primary
care (results not shown).
Conclusions
The results of this study suggest that individual- and area-level
factors should be taken into consideration when studying
variations in the use of prescription drugs. This is not to suggest
that such determinants of variation should be used to mask what
might otherwise be important disparities in use of treatments
across population subgroups. Instead, the analysis of variation in
medicine use should be used to illuminate determinants so that
Table 3. Summary statistics for regional variations in rates of purchasing one or more prescription from specific therapeutic
categories in 2006, non-rural local health areas of British Columbia.
Min Median Max Max-Min Ratio Inter-quartile ratio CV
Antihypertensives
Crude 0.08 0.16 0.23 2.67 1.27 0.18
Adjusted, individual 0.14 0.15 0.18 1.29 1.11 0.07
Adjusted, individual and area 0.13 0.15 0.16 1.22 1.05 0.04
Statins
Crude 0.04 0.07 0.11 2.91 1.20 0.20
Adjusted, individual 0.06 0.07 0.09 1.53 1.20 0.11
Adjusted, individual and area 0.06 0.07 0.08 1.36 1.11 0.07
Acid reducing drugs
Crude 0.05 0.08 0.11 2.20 1.16 0.14
Adjusted, individual 0.06 0.08 0.11 1.72 1.14 0.11
Adjusted, individual and area 0.06 0.08 0.10 1.57 1.08 0.08
Opioid drugs
Crude 0.07 0.13 0.16 2.28 1.22 0.18
Adjusted, individual 0.08 0.12 0.16 2.06 1.21 0.16
Adjusted, individual and area 0.10 0.11 0.13 1.31 1.10 0.07
Antidepressants
Crude 0.05 0.11 0.14 2.60 1.26 0.19
Adjusted, individual 0.06 0.11 0.14 2.23 1.22 0.17
Adjusted, individual and area 0.08 0.09 0.11 1.39 1.07 0.07
doi:10.1371/journal.pone.0015883.t003
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or planned for as appropriate [23]. At the individual level, for
example, the u-shaped income gradients found in this study
suggest that the income-based system of drug coverage in BC may
create prescription drug access barriers (particularly for lower-
middle-income households) that deserve further investigation. At
the contextual level, our findings concerning education, health
status, and concentrations of ethnic minorities all point to areas
requiring more in-depth investigation and possible intervention to
address inequities.
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